Obstetric and Neonatal Outcomes 1 or More Years After a Diagnosis of Breast Cancer.


Journal

Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101

Informations de publication

Date de publication:
01 12 2022
Historique:
received: 28 03 2022
accepted: 08 07 2022
pubmed: 12 11 2022
medline: 1 12 2022
entrez: 11 11 2022
Statut: ppublish

Résumé

To evaluate obstetric and neonatal outcomes of the first live birth conceived 1 or more years after breast cancer diagnosis. We performed a population-based study to compare live births between women with a history of breast cancer (case group) and matched women with no cancer history (control group). Individuals in the case and control groups were identified using linked data from the California Cancer Registry and California Office of Statewide Health Planning and Development data sets. Individuals in the case group were diagnosed with stage I-III breast cancer at age 18-45 years between January 1, 2000, and December 31, 2012, and conceived 12 or more months after breast cancer diagnosis. Individuals in the control group were covariate-matched women without a history of breast cancer who delivered during 2000-2012. The primary outcome was preterm birth at less than 37 weeks of gestation. Secondary outcomes were preterm birth at less than 32 weeks of gestation, small for gestational age (SGA), cesarean delivery, severe maternal morbidity, and neonatal morbidity. Subgroup analyses were used to assess the effect of time from initial treatment to fertilization and receipt of additional adjuvant therapy before pregnancy on outcomes of interest. Of 30,021 women aged 18-45 years diagnosed with stage I-III breast cancer during 2000-2012, 553 met the study inclusion criteria. Those with a history of breast cancer and matched women in the control group had similar odds of preterm birth at less than 37 weeks of gestation (odds ratio [OR], 1.29; 95% CI 0.95-1.74), preterm birth at less than 32 weeks of gestation (OR 0.77; 95% CI 0.34-1.79), delivering an SGA neonate (less than the 5th percentile: OR 0.60; 95% CI 0.35-1.03; less than the 10th percentile: OR 0.94; 95% CI 0.68-1.30), and experiencing severe maternal morbidity (OR 1.61; 95% CI 0.74-3.50). Patients with a history of breast cancer had higher odds of undergoing cesarean delivery (OR 1.25; 95% CI 1.03-1.53); however, their offspring did not have increased odds of neonatal morbidity compared with women in the control group (OR 1.15; 95% CI 0.81-1.62). Breast cancer 1 or more years before fertilization was not strongly associated with obstetric and neonatal complications.

Identifiants

pubmed: 36357983
doi: 10.1097/AOG.0000000000004936
pii: 00006250-990000000-00619
pmc: PMC9712170
mid: NIHMS1825301
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

939-949

Subventions

Organisme : NCI NIH HHS
ID : K08 CA234333
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001874
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA101642
Pays : United States

Informations de copyright

Copyright © 2022 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

Financial Disclosure Mark A. Clapp received payment from Delfina Care for serving on the advisory board (no relation to content of submitted work) and was not included in the decision to publish this. Jose Alejandro Rauh-Hain received payment from the NIH, Guidepoint, and the Schlesinger Group. He also received payment once as a speaker for J&J. The other authors did not report any potential conflicts of interest.

Références

Obstet Gynecol. 2007 Oct;110(4):849-54
pubmed: 17906019
J Cancer Surviv. 2018 Oct;12(5):702-711
pubmed: 30128858
Cancer. 2018 Nov 15;124(22):4401-4407
pubmed: 30403424
N Engl J Med. 2018 Aug 09;379(6):513-523
pubmed: 30089070
Obstet Gynecol. 2015 Apr;125(4):938-947
pubmed: 25751214
Ann Intern Med. 2019 Jan 1;170(1):22-30
pubmed: 30534999
Arch Dis Child. 2006 Feb;91(2):149-52
pubmed: 16174641
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Gynecol Oncol. 2008 Nov;111(2 Suppl):S105-10
pubmed: 18755501
Obstet Gynecol. 2021 Aug 1;138(2):e65-e90
pubmed: 34293771
PLoS Med. 2006 Sep;3(9):e336
pubmed: 16968117
Obstet Gynecol. 2021 Jun 1;137(6):1109-1118
pubmed: 33957660
Curr Oncol. 2015 Mar;22(Suppl 1):S8-S18
pubmed: 25848342
J Clin Oncol. 2021 Oct 10;39(29):3293-3305
pubmed: 34197218
Comput Biomed Res. 1997 Aug;30(4):290-305
pubmed: 9339323
PLoS One. 2013;8(3):e57817
pubmed: 23526952
Int J Cancer. 2013 Dec 1;133(11):2696-705
pubmed: 23729011
Pediatrics. 2019 Jul;144(1):
pubmed: 31201230
J Cancer Surviv. 2017 Feb;11(1):58-63
pubmed: 27480882
Breast Cancer Res Treat. 2019 Jul;176(2):419-427
pubmed: 31020470
Gynecol Oncol. 2006 May;101(2):315-21
pubmed: 16310839
J Adolesc Young Adult Oncol. 2016 Sep;5(3):240-7
pubmed: 27111543
Am J Obstet Gynecol. 2011 Aug;205(2):103-10
pubmed: 21411052
Pediatrics. 2006 Jan;117(1):154-60
pubmed: 16396873
Int J Cancer. 2017 Dec 1;141(11):2187-2196
pubmed: 28836277
Obstet Gynecol. 2018 May;131(5):899-908
pubmed: 29630020
Int J Cancer. 2010 Oct 1;127(7):1669-79
pubmed: 20054856
Am J Obstet Gynecol. 2006 Apr;194(4):992-1001
pubmed: 16580288
Int J Cancer. 2018 May 15;142(10):1994-2002
pubmed: 29266267
Cancer. 2012 Mar 15;118(6):1710-7
pubmed: 21887678
Obstet Gynecol. 2020 Dec;136(6):1157-1169
pubmed: 33156194
Cancer Control. 2008 Jan;15(1):55-62
pubmed: 18094661
Int J Cancer. 2011 Sep 1;129(5):1225-36
pubmed: 21387311
Am J Obstet Gynecol. 2010 Apr;202(4):335-43
pubmed: 20060513
J Clin Oncol. 2011 May 1;29(13):1670-7
pubmed: 21444865
Breast Cancer Res Treat. 2011 Sep;129(2):309-17
pubmed: 21698406
Birth. 2015 Dec;42(4):309-18
pubmed: 26489891
Obstet Gynecol. 1999 Jan;93(1):9-14
pubmed: 9916947
Cancer. 2015 Nov 15;121(22):3938-47
pubmed: 26264701
Natl Vital Stat Rep. 2019 Nov;68(13):1-47
pubmed: 32501202
Oncologist. 2015 Feb;20(2):186-95
pubmed: 25568146
JCO Oncol Pract. 2021 Jun;17(6):305-313
pubmed: 33449828
Br J Cancer. 2006 Jan 16;94(1):142-6
pubmed: 16306874
Breast Cancer Res Treat. 2009 Sep;117(2):319-24
pubmed: 19137426
J Clin Oncol. 2010 Apr 1;28(10):1727-32
pubmed: 20194858
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Cancer. 2016 Apr 1;122(7):988-99
pubmed: 26849003
Breast Cancer Res Treat. 2009 Jul;116(2):215-23
pubmed: 19390962
Gynecol Oncol. 2012 May;125(2):477-82
pubmed: 22245711
PLoS One. 2014 Dec 08;9(12):e113292
pubmed: 25485774

Auteurs

Kirsten Jorgensen (K)

Department of Gynecologic Oncology and Reproductive Medicine, the Department of Breast Oncology, the Department of Health Services Research, and the Division of Cancer Prevention and Population Sciences, the University of Texas MD Anderson Cancer Center, and the University of Texas Health Science Center at Houston, Houston, Texas; the UNC Gillings School of Global Public Health, Chapel Hill, North Carolina; the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, NewYork-Presbyterian/Columbia University Medical Center, and the Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, New York; and the Department of Obstetrics and Gynecology, Maternal-Fetal Medicine Program, Massachusetts General Hospital, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH